A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence

American Journal on Addictions

Volumn 18, Issue 1, 2009, Pages 53-64

  Carpenter, Kenneth M ^a,b   McDowell, David ^a,b,c   Brooks, Daniel J ^a   Cheng, Wendy Y ^a,b   Levin, Frances R ^a,b,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CANNABIS; NEFAZODONE; PLACEBO; RIBOFLAVIN;

ACNE; ADD ON THERAPY; ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BEDTIME DOSAGE; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; COPING BEHAVIOR; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUSCLE TWITCH; NAUSEA; NIGHTMARE; OUTPATIENT; POLLAKISURIA; PROBABILITY; RASH; SEDATION; SIDE EFFECT; SKILL; SKIN DEFECT; SUSTAINED DRUG RELEASE; SWEATING; TREMOR; UNPLEASANT DREAM; URINARY TRACT DISEASE; VAGINA DISCHARGE; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME; TRIAZOLES;

EID: 60549087360     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802408936     Document Type: Article

References (57)

1. NIDA. NIDA Research Reports. Available at: http://www.nida.nih.gov/ ResearchReports/Marijuana/. Accessed 1 October 2008.
2. Stinson F, Ruan W, Pickering R, Grant B. Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychol Med. 2006;36:1447-1460.
3. Kalant H. Adverse effects of cannabis on health: An update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:849-863.
4. Brook JS, Cohen P, Brook DW. Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiatry. 1998;37:322-330.
5. Gruber AJ, Pope HG, Hudson JI, Yurgelun-Todd D. Attributes of long-term heavy cannabis users: A case-control study. Psychol Med. 2003;33:1415-1422.
6. Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: A review. Addiction. 2000;95:1621-1630.
7. Tashkin DP, Fligiel S, Wu TC, et al. Effects of habitual use of marijuana and/or cocaine on the lung. NIDA Res Monogr. 1990;99:63-87.
8. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF III. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45:24-30.
9. Compton WM, Pringle B. Services research on adolescent drug treatment. Commentary on "The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials". J Subst Abuse Treat. 2004;27:195-196.
10. SAMSHA. National Survey on Drug Use and Health. Available at: http://www.oas.samsha.gov/nsduh.htm. Accessed 3 October 2008.
11. MTPRG, Marijuana Treatment Project Research Group (MTPRG). Brief treatments for cannabis dependence: Findings from a randomized multisite trial. J Consult Clin Psychol. 2004;72:455-466.
12. Litt MD, Kadden RM, Stephens RS. The Marijuana Treatment Research Group. Coping and self-efficacy in marijuana treatment: Results from the Marijuana Treatment Project. J Consult Clin Psychol. 2005;73:1015-1025.
13. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: A test of the relapse prevention model. J Consult Clin Psychol. 1994;62:92-99.
14. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000;68:898-908.
15. Project MATCH Research group. Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes. Alcohol Clin Exp Res. 1998;22:1300-1311.
16. Carroll KM. Relapse prevention as a psychosocial treatment: A review of controlled clinical trials. Exp Clin Psychopharmacol. 1996;4:46-54.
17. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol. 2000;68:1051-1061.
18. O'Malley SS, Kosten TR. Pharmacotherapy of addictive disorders. In: Miller WR, Carroll KM, eds. Rethinking Substance Abuse: What the Science Shows, and What We Should Do about It. New York: Guilford Press; 2006:240-256.
19. Cornelius J, Salloum I, Haskett R. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav. 1999;24:111-114.
20. McRae A, Budney A, Kathleen K. Treatment of marijuana dependence: A review of the literature. J Subst Abuse Treat. 2003; 24:369-376.
21. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19:233-238.
22. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161:1967-1977.
23. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl). 1999;141:385-394.
24. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl). 1999;141:395-404.
25. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marijuana smoking on group interaction and individual behavior. Compr Psychiatry. 1979;20:427-432.
26. Mendelson J. Marijuana withdrawal syndrome in a woman. Am J Psychiatry. 1984;141:1289-1290.
27. Glassman A. Psychiatry and cigarettes. Arch Gen Psychiatry. 1998;55:692-693.
28. Davidson J, Connor K. Bupropion sustained release: A therapeutic overview. J Clin Psychiatry. 1998;59:25-31.
29. Haney M., Ward A S, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155:171-179.
30. Levin F, Evans S, McDowell D, Brooks D, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21:1-16.
31. Solhkhah R, Wilens T, Daly J, Prince J, VanPatten S, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol. 2005;15:777-786.
32. Elkashef A, Rawson R, Anderson A, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33:1162-1170.
33. Mooney ME, Sofuoglu M. Bupropion for the treatment of nicotine withdrawal and craving. Expert Rev Neurother. 2006;6:965-981.
34. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56 (Suppl. 6):12-21.
35. Thase ME. Treatment of severe depression. J Clin Psychiatry. 2000;61(Suppl. 1):17-25.
36. Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl). 2003;165:157-165.
37. Passos S, Camacho L, Lopes C, dos Santos M. Nefazodone in out-patient treatment of inhaled cocaine dependence: A randomized double-blind placebo-controlled trial. Addiction. 2005;100:489-494.
38. Ciraulo D, Knapp C, Rotrosen J, et al. Nefazodone treatment of cocaine-dependence with comorbid depressive symptoms. Addiction. 2005;100(Suppl.):23-31.
39. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: A double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13:21-32.
40. Nordstrom B, Levin FR. Treatment of cannabis use disorders: A review of the literature. Am J Addict. 2007;16:331-342.
41. Hall S, Reus V, Munez R, et al. Cognitive behavior therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55:683-690.
42. First MB, Spitzer RL, Gibbon M, William JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Patient Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
43. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders (4th ed., text revision ed.). Washington, DC: American Psychiatric Association; 1994.
44. Kadden R, Carroll K, Donovan D, et al. Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. NIAAA Project Match Monograph Series. Vol. 3. Rockville, Md.: National Institutes of Health; 1995.
45. Carroll KM. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. Bethesda, Md.: National Institutes of Health; 2000.
46. National Institute on Drug Abuse. NIDA Research Monograph 73. Washington, DC: U.S. Government Print Office; 1986.
47. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md.: National Institute for Mental Health; 1976.
48. Ellis B, Johns M, Lancaster R, Raptopoulos P, Angelopoulos N, Priest R. The St. Mary's Hospital sleep questionnaire: A study of reliability. Sleep. 1981;4:93-97.
49. Leigh T, Bird H, Hindmarch I, Constable P, Wright V. Factor analysis of the St. Mary's Hospital Sleep Questionnaire. Sleep. 1988;11:448-453.
50. Oyefeso A, Sedgwick P, Ghodse H. Subjective sleep-wake parameters in treatment-seeking opiate addicts. Drug Alcohol Depend. 1997;48:9-16.
51. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White J. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100:1320-1329.
52. Snaith R, Constantopoulos A, Jardine M, McGuffin P. A clinical scale for the self-assessment of irritability. Br J Psychiatry. 1978;132:164-171.
53. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959;32:50-55.
54. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry. 1969;3:76-79.
55. Kadden RM, Litt MD, Kabela-Cormier E, Petry NM. Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav. 2007;32:1220-1236.
56. Hawks RL, Chiang CN. Examples of specific drug assays. NIDA Res Monogr. 1986;73:84-112.
57. Evans SM, Levin FR, Brooks DJ, Garawi F. Memantine treatment for alcohol dependence: Implementation of contingency management procedures to enhance clinical trials. Alcohol Clin Exp Res. 2007;31:775-782.